相关实验视频

Updated: May 1, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

在人体细胞中对CYP2C19的深度突变扫描揭示了基质特异性-丰度权衡

Gabriel E Boyle¹, Katherine A Sitko¹, Jared G Galloway²

¹Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.

|September 25, 2024

概括

细胞染色体P450酶的遗传变异会影响药物代谢和安全性. 通过比较CYP2C19和CYP2C9变体,可以发现这些关键药物代谢酶的差异是如何产生的,从而改善了个性化医疗方法.

科学领域:

生物化学生物化学
药物基因组学药物基因组学
酶学是一种酶学.

背景情况:

细胞染色体P450酶对于药物代谢至关重要,其中的变异影响了疗效和安全性.
预测变异效应是困难的,因为低序列保存,即使在密切相关的酶,如CYP2C9和CYP2C19.

研究的目的:

调查单氨基酸变体对CYP2C19.19中蛋白质丰度的影响.
为了比较同源酶CYP2C19和CYP2C9之间的变异效应,以了解功能差异.
确定负责功能差异和进化权衡的区域.

主要方法:

大规模并行测序用于测量CYP2C19.19中数千个变异的稳定状态蛋白质丰度.
对4,670种CYP2C19和CYP2C9.9共同的变体的变体丰度数据的比较分析.
在CYP2C19和CYP2C9之间系统地交换野生类型的氨基酸,以评估功能影响.

主要成果:

确定了影响细胞染色体P450功能和变体丰度的关键位置和结构特征.
在CYP2C19和CYP2C9.9之间的基质识别位点中揭示了不同的变异丰度模式.
发现CYP2C19特定区域的替代减少了蛋白质丰富度,在多个突变中具有复杂的相互作用.

结论:

同类CYP450酶之间的变异效应不同,特别是在基质识别位点,表明进化权衡.
了解这些差异可以进一步了解细胞染色体P450的功能分歧,并有助于预测药物反应.
对未注释变体的分析表明,很大一部分影响蛋白质的稳定性和功能.

关键词:

细胞染色体P450的使用.深度突变扫描 (deep mutational scanning) 是一种对突变进行深度扫描的方法.基质特异性基质特异性热力学稳定性热力学稳定性

更多相关视频

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Author Spotlight: Advancing Real-Time cAMP Detection in Cells Using cADDis Biosensor

Author Spotlight: Advancing Real-Time cAMP Detection in Cells Using cADDis Biosensor

Published on: March 22, 2024

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...